Free Trial
NYSEAMERICAN:HEB

Hemispherx BioPharma (HEB) Stock Price, News & Analysis

Hemispherx BioPharma logo
$6.70 -1.68 (-20.05%)
As of 06/13/2025

About Hemispherx BioPharma Stock (NYSEAMERICAN:HEB)

Key Stats

Today's Range
$5.80
$9.00
50-Day Range
$0.09
$8.38
52-Week Range
$1.69
$14.81
Volume
7,639 shs
Average Volume
102,599 shs
Market Capitalization
$16.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive HEB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemispherx BioPharma and its competitors with MarketBeat's FREE daily newsletter.

HEB Stock News Headlines

The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
Hemispherx Biopharma earnings preview: what Wall Street is expecting
H-E-B hosting hiring fairs
See More Headlines

HEB Stock Analysis - Frequently Asked Questions

Hemispherx BioPharma's stock was trading at $0.2170 at the beginning of the year. Since then, HEB shares have increased by 2,987.6% and is now trading at $6.70.

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) issued its quarterly earnings results on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) earnings per share for the quarter, beating analysts' consensus estimates of ($1.70) by $0.63. The specialty pharmaceutical company had revenue of $0.03 million for the quarter.

Shares of Hemispherx BioPharma reverse split before market open on Tuesday, June 11th 2019.The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 10th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Shares of HEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hemispherx BioPharma investors own include NewLink Genetics (NLNK), Goodrich Petroleum (GDPMQ), Biocept (BIOC), CTI BioPharma (CTIC), Inovio Pharmaceuticals (INO), Palatin Technologies (PTN) and Ayala Pharmaceuticals (ADXS).

Company Calendar

Last Earnings
8/15/2019
Today
7/15/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:HEB
Previous Symbol
NYSE:HEB
CIK
946644
Fax
N/A
Employees
31
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
2,442,000
Free Float
N/A
Market Cap
$16.36 million
Optionable
Not Optionable
Beta
N/A
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NYSEAMERICAN:HEB) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners